With High Tide, Sanity Group and now Curaleaf all fortifying their positions, Germany’s medical cannabis market is becoming a strategic battleground for international operators.
The announcement came quietly — no fanfare, no press conference — but the strategic signal was loud. On April 30, 2026, Curaleaf Holdings completed the buyout of the remaining 45% stake in Four 20 Pharma GmbH, converting a four-year-old minority investment into full corporate ownership. The deal closes a chapter that began in August 2022, when the U.S. multi-state operator first acquired a 55% majority stake for €19.7 million, framing Germany as its gateway to a then-anticipated adult-use boom.
That boom never came. But Curaleaf stayed — and just doubled down.
Full Ownership, Full Intent
The financial terms of the final tranche were not disclosed. What is clear is what Curaleaf now controls: a fully EU-GMP and GDP-licensed producer and distributor with an established network serving pharmacies, nursing homes, and research institutions across Germany and select European markets. Add to that owned cultivation in Portugal and Canada, and Curaleaf now operates a vertically integrated seed-to-patient supply chain anchored in the continent’s largest medical cannabis market.
CEO Boris Jordan framed the move as a long-term commitment: the acquisition “reinforces our commitment to Europe and underscores the strategic importance of building high-quality, locally anchored operations in a market that will continue to grow exponentially.”
The Four 20 brand is already traveling — it has launched in the United Kingdom and Poland, with further international markets planned. Germany, in other words, is now the production anchor for a broader European brand rollout.
Germany Is Becoming a Chessboard
What makes this development particularly significant is the company it keeps. Curaleaf’s consolidation move doesn’t happen in isolation — it arrives at a moment when Germany’s medical cannabis market is quietly being carved up by international players who are making their long-term bets.
Sanity Group, backed by blue-chip investors and positioned as a compliance-first medical operator, has spent years building infrastructure and brand credibility in the German prescribing ecosystem. High Tide, the Canadian retail-and-brand operator behind the Canna Cabana model, has been expanding its European footprint aggressively — most recently reinforcing its German presence through its Remexian Pharma subsidiary, which is actively building out pharmacy partnerships and physician-facing infrastructure.
And now Curaleaf — the largest cannabis company by revenue in the world — removes any ambiguity about where it sees its next chapter being written.
What This Means for the Market
For operators, investors, and founders watching Germany from the outside, the pattern is unmistakable: the window for establishing a scalable, compliant presence in the German market is narrowing. The early-mover advantage is being locked in by well-capitalised international players who are no longer scouting — they are building.
This does not mean the market is closed. Germany’s patient numbers continue to grow, the prescribing base is expanding, and the pharmacy channel remains fragmented enough to reward specialist operators and niche brands. But the structural positions — the GMP licenses, the import approvals, the distributor relationships — are increasingly being claimed.
For those still on the sidelines, Germany’s message in 2026 is simple: the race is on, and the front runners are pulling away.
